Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 6/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23235435 | 0.72 | KDM4E (0.57) | KDM4EALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL5045994 | 0.71 | KDM4E (0.88) | KDM4EALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL23000102 | 0.64 | KDM4E (0.47) | KDM4EALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL5049423 | 0.62 | RAD52 (0.88) | KDM4EALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL16942561 | 0.61 | MEN1 (0.45) | KDM4EALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL23235443 | 0.60 | POLB (0.41) | KDM4EALDH1A1MAPTLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL23909168 | 0.59 | ACHE (0.42) | KDM4EALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL23000076 | 0.59 | KDM4E (0.52) | KDM4EALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL23000115 | 0.59 | KDM4E (0.56) | KDM4EALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL12374 | 0.58 | HRH3 (0.67) | ALDH1A1TSHRTDP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338240-B2 | Nonmuscle myosin ii inhibitors | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250163056-A1 | NONMUSCLE MYOSIN II INHIBITORS | THE UNIV OF FLORIDA RESEARCH FOUNDATION INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20230227452-A1 | NONMUSCLE MYOSIN II INHIBITORS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227452-A1 | NONMUSCLE MYOSIN II INHIBITORS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-11649234-B2 | Nonmuscle myosin II inhibitors for substance use relapse | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649234-B2 | Nonmuscle myosin II inhibitors for substance use relapse | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649234-B2 | Nonmuscle myosin II inhibitors for substance use relapse | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20210317117-A1 | NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-14 | — | — | US | disclosed |
| US-20210317117-A1 | NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163056-A1 | NONMUSCLE MYOSIN II INHIBITORS | MYH2, MYO3B, MYO1B | KDM4E 3550/4885ALDH1A1 2712/4885MAPT 353/4885 |
| US-20230227452-A1 | NONMUSCLE MYOSIN II INHIBITORS | MYH2, MYO3B, MYO1B | KDM4E 3550/4885ALDH1A1 2712/4885MAPT 353/4885 |
| US-20210317117-A1 | NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE | MYH2, MYO3B, MYO1B | KDM4E 3535/4885ALDH1A1 1902/4885MAPT 441/4885 |
| US-12338240-B2 | Nonmuscle myosin ii inhibitors | MYH2, MYO3B, MYO1B | KDM4E 3550/4885ALDH1A1 2712/4885MAPT 353/4885 |
| US-11649234-B2 | Nonmuscle myosin II inhibitors for substance use relapse | MYH2, MYO3B, MYO1B | KDM4E 3535/4885ALDH1A1 1902/4885MAPT 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.